Selective serotonin reuptake inhibitors and related antidepressant compounds have the
secondary pharmacologic property of inhibiting the activity of human cytochrome P450 …

Preclinical and clinical studies support the rationale that development of single molecules,
which would promote serotonergic and noradrenergic neurotransmission by inhibiting …

Se ha dicho que todo se convierte en un círculo completo o, en palabras modernas," lo que
da vueltas vuelve". En 1885, con la primera edición de Remington, el editor de este libro era …

The pharmacokinetics and safety of duloxetine were evaluated in a single‐blind, placebo‐
controlled, escalating multiple‐dose study in 12 healthy male subjects. In the treatment …

As patients age, adverse drug reactions increase dramatically in frequency and severity.
Although the population of elderly patients in controlled studies of antidepressants is small …

Major depressive disorder is a widespread condition with antidepressants as the main
pharmacological treatment. However, some patients experience concerning adverse …

Objective: To characterize the response to the serotonin and norepinephrine reuptake
inhibitor, venlafaxine extended release (XR), during the long-term treatment of generalized …

An open‐label study evaluated the effect of steady‐state venlafaxine on the single‐dose
pharmacokinetic profile of risperidone, a CYP2D6 substrate; its active metabolite, 9 …

Venlafaxine is a clinically effective antidepressant. Caffeine is a metabolic probe for the
quantitative measurement of CYP1A2 activity in vivo. This open‐label study evaluated the …

The effect of steady-state venlafaxine administration on the single-dose pharmacokinetic
profile of terfenadine, a cytochrome pigment (P450) isoenzyme CYP3A4 substrate, and its …